Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) and Aries Science & Technology announced the issuance of Patent No. 12,059,393 to Enveric's subsidiary, Akos Biosciences, for a topical product aimed at treating radiation dermatitis. This condition affects approximately two million cancer patients annually, with a market opportunity estimated at $400 million. The patent issuance follows a Licensing Agreement between Aries and Akos for the clinical development of the CBD-based lotion. Aries is forming a subsidiary to advance this opportunity, with Dr. Hari Harikumar nominated as Chairman-elect. Under the agreement terms, Enveric could receive up to $61 million in milestone payments and tiered royalties ranging from 2.5% to 10% on future sales.
Enveric Biosciences (NASDAQ: ENVB) reported Q2 2024 financial results and provided a corporate update. The company prioritized EB-003 as its lead development candidate, a novel non-hallucinogenic neuroplastogenic molecule for treating severe mental health disorders. Preclinical results confirmed EB-003's oral bioavailability and significant brain exposure, supporting an expedited development strategy.
Key highlights include:
- Expanded business development activities with multiple deals in advanced stages
- Signed licensing agreement with Aries Science & Technology for radiation dermatitis product
- Targeting IND filing for EB-003 by Q3 2025 and first-in-human trial by end of 2025
- Q2 2024 net loss of $1.7 million ($0.23 per share) compared to $6.40 million ($3.04 per share) in Q2 2023
- Cash-on-hand of $3.5 million as of June 30, 2024
Enveric Biosciences (NASDAQ: ENVB) announced promising preclinical results for EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The study revealed good oral bioavailability and significant brain exposure in rodent models, with a brain:plasma exposure ratio of ~1.5. EB-003 also demonstrated stability against human monoamine oxidase-A (MAO-A) and in various liver microsomes, unlike DMT and similar analogs.
Based on these results, Enveric is accelerating EB-003's evaluation in animal efficacy models. The company expects to file an IND application by Q3 2025 and initiate clinical development by the end of 2025. This advancement supports Enveric's patient-centered approach, aiming to develop non-hallucinogenic treatments with favorable pharmacological properties that enhance patient adherence and reduce treatment burden.
Enveric Biosciences (NASDAQ: ENVB) and Aries Science & Technology have announced a licensing agreement for the clinical development of Enveric's patented radiation dermatitis topical product. This condition affects approximately two million cancer patients annually, with a market opportunity estimated at $400 million. The agreement includes potential milestone payments of up to $61 million and tiered royalties ranging from 2.5% to 10% on future sales for Enveric. Aries has nominated Dr. Hari Harikumar as Chairman-elect of a subsidiary formed to advance this opportunity. This partnership allows Enveric to focus on neuropsychiatric indications while Aries develops the cancer support care product.
Enveric Biosciences announces that the United States Patent and Trademark Office has granted Patent No. 11,945,778 for its drug candidate EB-002. This new patent expands Enveric’s intellectual property by covering methods of treatment for a broad range of brain neurological disorders including sleep disorders, depression, substance-related disorders, and headaches.
EB-002, a next-generation psilocin prodrug initially developed for neuropsychiatric disorders such as anxiety, now holds three US patents covering its compositions, formulations, and methods of treatment. CEO Joseph Tucker highlights that this enhanced patent protection will help accelerate EB-002's clinical development and broaden its applicability to a wider patient population.
Enveric Biosciences (NASDAQ: ENVB) has announced that it is prioritizing the development of its novel neuroplastogenic molecule, EB-003. EB-003 is designed to treat severe mental health disorders such as depression, anxiety, and addiction without causing the hallucinogenic effects often associated with psychedelic-based treatments. The company is advancing pre-clinical development and plans to meet with the FDA for a Pre-IND discussion in early 2025. EB-003 aims to overcome key issues identified by the FDA's advisory committee regarding hallucinogenic psychedelics, such as 'expectation bias' and the need for psychotherapy co-administration. Early data shows EB-003 can bind to the 5-HT2A receptor and induce neuroplasticity without significant hallucinogenic side effects in animal models, paving the way for further human clinical studies.
Enveric Biosciences (NASDAQ: ENVB), a company focused on developing innovative neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders, announced its participation in the 2024 BIO International Convention. The event takes place in San Diego, CA, from June 3-6, 2024. Enveric aims to engage with potential investment and development partners to explore collaborations for its promising drug candidates. CEO Joseph Tucker emphasized the significant interest from strategic partners in the pharmaceutical industry for Enveric's drug discovery assets.
Enveric Biosciences (NASDAQ: ENVB) reported financial and corporate results for the first quarter of 2024, ending March 31. The company unveiled seven classes of novel drug candidates from its Psybrary™ and PsyAI™ platforms. A business development campaign resulted in seven non-binding term sheets with four strategic partners, potentially totaling $410 million in milestone payments plus future royalties. Enveric's lead drug candidate, EB-003, is advancing towards an IND application and Phase 1 clinical trial. Proceeds from warrant exercises and investment options raised $4.5 million. The company's net loss for Q1 2024 was $2.46 million, with cash-on-hand at $6.36 million.
Enveric Biosciences, Inc (ENVB) signed a non-binding term sheet with an undisclosed biotechnology company for the exclusive license to patented methods of treating breast and other cancers using cannabinoids in combination with chemotherapeutic drugs. The licensee will receive an exclusive global license, assume responsibility for development, and pay Enveric up to $61 million in milestones and royalties. The agreement aims to advance novel treatment regimens for cancer patients, with a potential impact on breast and other cancer treatments.
Summary not available.